Patrick A. Mcbrayer

Biography

 Patrick A. McBrayer joined ACell as President and Chief Executive Officer in 2016. Mr. McBrayer is on the Board of Directors of Misonix Inc, which markets therapeutic ultrasound medical devices world-wide. He has recently advised medical device companies in spine, orthopedics and biotechnology. Mr. McBrayer was President and Chief Executive Officer of AxioMed Spine Corporation until the company was acquired in 2014. AxioMed focused on restoring the native function of the spine with the company’s Freedom total disc spine technology. Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He was also a Founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999. Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology (acquired by Medtronic Inc.). He has been responsible for a number of private placements, as well as Osteotech and Exogen’s public offerings. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc. He has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. Mr. McBrayer is a graduate of the United States Military Academy at West Point.

Research Interest

 Regenerative medicine, Wound management procedures, Surgical matrix, Surgical soft tissue repair